La Jolla Interdisciplinary Neuroscience Center Cores - Structural Bio Core Salk

拉霍亚跨学科神经科学中心核心 - 结构生物核心 Salk

基本信息

项目摘要

STRUCTURAL BIOLOGY CORE 1 . MAIN OBJECTIVES AND NEW DIRECTIONS The use of Structural Biology on the La Jolla Torrey Pines Mesa has increased tremendously over the past 5 years. For example, BIMR has added 4 new faculty members as major users of its Structural Biology Facility and is directed by crystallography Robert Liddington. However, presently this Core is part of the Burnham NIH-funded Cancer Center with little or no access to neuroscientists on the La Jolla Torrey Pines Mesa. Additionally, two faculty at The Salk are also heavily invested in crystallography but heretofore were not organized as a Core and thus have little interaction with neuroscientists. Moreover, the Head of NMR at UCSD, Stan Opella, is world-renowned in this area and has an NMR facility that would be made available to neuroscientists on this grant as a satellite core. Hence, the structural core will function with headquarters at BIMR and satellite facilities at The Salk Institute and UCSD. This Structural Core will foster collaborative interactions by allowing equal access to neuroscientists. BIMR has made major investments in instrumentation for structural biology, including the acquisition of three new NMR spectrometers and upgrades for the X-ray diffraction set up. UCSD has installed a state-or-the-art 900 MHz spectrometer, which will be available for collaborations of neuroscientists. Scientific progress has been impressive in the recent past by these facilities, including 6 papers in the journals Cell, Science and Nature that utilized structural data from the facilities. However, Neuroscientists have had minimal, if any, access to the faculty or instrumentation because they are located within the Cancer Centers at BIMR, TSRI, UCSD, and The Salk. The current grant will rectify this by making the facility and the faculty available to Neuroscientists as a Core Unit. In summary, the Structural Biology Core comprises two facilities: Crystallography and NMR. Scientific, logistical, and budgetary issues provide justification for this merger of services. The primary application of Crystallography and NMR overlap, and most research projects require both Crystallography and NMR. The merged facility serves the needs of users with a broad range of expertise. There are several neuroscience investigators who are not mainstream structural biologists but who have a desire to learn structural techniques. The facility provides appropriate training and direction for these people. Other "hardcore" structural groups require much less support, and the facility will primarily supply the necessary hardware and technical support to achieve the scientific goals. One manager (who is free to this grant) oversees both techniques within the Structural Biology Facility and provides the necessary training (in conjunction with the faculty supervisors); technicians paid for by the current grant will coordinate the efforts at the three centers (BIMR, Salk, UCSD, and facilitate TSRI neuroscientist access as well). Future plans include a protein expression facility in this Core.
结构生物学核心 1。主要目标和新方向 在La Jolla Torrey Pines Mesa上使用结构生物学的使用已大大增加 过去5年。例如,BIMR在其主要用户中增加了4位新教师 结构生物学设施,由晶体学罗伯特·利丁顿(Robert Liddington)导演。但是,目前 该核心是Burnham NIH资助的癌症中心的一部分,几乎没有或根本无法获得神经科学家 在La Jolla Torrey Pines Mesa上。此外,Salk的两个教师也投入了大量投资 晶体学,但迄今为止没有作为核心组织,因此与 神经科学家。此外,Stan Opella的UCSD的NMR负责人在该地区享誉世界 并设有NMR设施,该设施将作为卫星提供给神经科学家 核。因此,结构核心将在BIMR和卫星设施的总部工作 Salk Institute和UCSD。这种结构核心将通过允许平等来促进协作互动 访问神经科学家。 BIMR对结构生物学仪器进行了重大投资, 包括获取三个新的NMR光谱仪和X射线衍射集的升级 向上。 UCSD已安装了状态或ART 900 MHz光谱仪,可用于 神经科学家的合作。最近,科学进步令人印象深刻 设施,包括期刊细胞中的6篇论文,科学和自然,这些论文利用了结构数据 设施。但是,神经科学家的访问权限很小,或 仪器是因为它们位于BIMR,TSRI,UCSD和 Salk。当前的赠款将通过使该设施和教职员工纠正这一点 神经科学家作为核心单位。 总之,结构生物学核心包括两个设施:晶体学和NMR。 科学,后勤和预算问题为这项服务合并提供了理由。主要 晶体学和NMR重叠的应用,大多数研究项目都需要 晶体学和NMR。合并的设施满足了用户的需求 专业知识。有几位神经科学研究者不是主流结构生物学家 但是谁渴望学习结构技术。该设施提供了适当的培训和 这些人的方向。其他“硬核”结构群需要更少的支持,而 设施将主要提供必要的硬件和技术支持以实现科学 目标。一位经理(他是免费获得这笔赠款的人)监督结构生物学中的两种技术 设施并提供必要的培训(与教师主管结合);技术人员 由当前赠款支付的将协调三个中心的努力(BIMR,SALK,UCSD和 也有助于TSRI神经科学家的访问)。未来计划包括蛋白质表达设施 核。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STUART A LIPTON其他文献

STUART A LIPTON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STUART A LIPTON', 18)}}的其他基金

Crosstalk between innate-immunity human microglia and adaptive-immunity Tregs in Alzheimer's disease
阿尔茨海默病中先天免疫人类小胶质细胞和适应性免疫 Tregs 之间的串扰
  • 批准号:
    10686979
  • 财政年份:
    2022
  • 资助金额:
    $ 12.2万
  • 项目类别:
Crosstalk between innate-immunity human microglia and adaptive-immunity Tregs in Alzheimer's disease
阿尔茨海默病中先天免疫人类小胶质细胞和适应性免疫 Tregs 之间的串扰
  • 批准号:
    10515987
  • 财政年份:
    2022
  • 资助金额:
    $ 12.2万
  • 项目类别:
Leadership in AD/ADRD Drug Discovery
AD/ADRD 药物发现领域的领导地位
  • 批准号:
    10193424
  • 财政年份:
    2021
  • 资助金额:
    $ 12.2万
  • 项目类别:
Leadership in AD/ADRD Drug Discovery
AD/ADRD 药物发现领域的领导地位
  • 批准号:
    10687169
  • 财政年份:
    2021
  • 资助金额:
    $ 12.2万
  • 项目类别:
Leadership in AD/ADRD Drug Discovery
AD/ADRD 药物发现领域的领导地位
  • 批准号:
    10461746
  • 财政年份:
    2021
  • 资助金额:
    $ 12.2万
  • 项目类别:
Pro-Electrophilic Drugs PEDs for Alzheimer's Disease
用于治疗阿尔茨海默病的亲电药物 PED
  • 批准号:
    10230417
  • 财政年份:
    2020
  • 资助金额:
    $ 12.2万
  • 项目类别:
Pro-Electrophilic Drugs PEDs for Alzheimer's Disease
用于治疗阿尔茨海默病的亲电药物 PED
  • 批准号:
    10256731
  • 财政年份:
    2020
  • 资助金额:
    $ 12.2万
  • 项目类别:
S-Nitrosylation-Induced Posttranslational Modification and Aberrant Cell Signaling in Sporadic Alzheimer's Disease
散发性阿尔茨海默病中 S-亚硝基化诱导的翻译后修饰和异常细胞信号转导
  • 批准号:
    9919542
  • 财政年份:
    2017
  • 资助金额:
    $ 12.2万
  • 项目类别:
S-Nitrosylation-Induced Posttranslational Modification and Aberrant Cell Signaling in Sporadic Alzheimer's Disease
散发性阿尔茨海默病中 S-亚硝基化诱导的翻译后修饰和异常细胞信号转导
  • 批准号:
    9355868
  • 财政年份:
    2017
  • 资助金额:
    $ 12.2万
  • 项目类别:
Novel Proteomics Approach to HIV-Associated Neurocognitive Disorder & Drug Abuse
治疗 HIV 相关神经认知障碍的蛋白质组学新方法
  • 批准号:
    9884749
  • 财政年份:
    2016
  • 资助金额:
    $ 12.2万
  • 项目类别:

相似国自然基金

跨区域调水工程与区域经济增长:效应测度、机制探究与政策建议
  • 批准号:
    72373114
  • 批准年份:
    2023
  • 资助金额:
    40 万元
  • 项目类别:
    面上项目
农产品区域公用品牌地方政府干预机制与政策优化研究
  • 批准号:
    72373068
  • 批准年份:
    2023
  • 资助金额:
    41 万元
  • 项目类别:
    面上项目
新型城镇化与区域协调发展的机制与治理体系研究
  • 批准号:
    72334006
  • 批准年份:
    2023
  • 资助金额:
    167 万元
  • 项目类别:
    重点项目
我国西南地区节点城市在次区域跨国城市网络中的地位、功能和能级提升研究
  • 批准号:
    72364037
  • 批准年份:
    2023
  • 资助金额:
    28 万元
  • 项目类别:
    地区科学基金项目
多时序CT联合多区域数字病理早期预测胃癌新辅助化疗抵抗的研究
  • 批准号:
    82360345
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Molecular Phenotyping Core
分子表型核心
  • 批准号:
    8016405
  • 财政年份:
    2010
  • 资助金额:
    $ 12.2万
  • 项目类别:
Role of disulfide bridges in the folding of conotoxins
二硫键在芋螺毒素折叠中的作用
  • 批准号:
    8019217
  • 财政年份:
    2010
  • 资助金额:
    $ 12.2万
  • 项目类别:
The Genetic Basis of Hereditary Liver Disease
遗传性肝病的遗传基础
  • 批准号:
    7994258
  • 财政年份:
    2010
  • 资助金额:
    $ 12.2万
  • 项目类别:
Integrated Molecular Core for Rehabilitation Medicine
康复医学综合分子核心
  • 批准号:
    8053664
  • 财政年份:
    2010
  • 资助金额:
    $ 12.2万
  • 项目类别:
OSU Crystallography Facility: Acquisition of Crystallization Robot
OSU 晶体学设施:购置结晶机器人
  • 批准号:
    7794649
  • 财政年份:
    2010
  • 资助金额:
    $ 12.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了